Frequently Asked Questions about NewAmsterdam Pharma Company N.V. (NAMS)

Name: NewAmsterdam Pharma Company N.V. (NAMS) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does NewAmsterdam Pharma Company N.V. (NAMS) do?

Accepted Answer

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which h...

Question 2

Is NewAmsterdam Pharma Company N.V. (NAMS) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of NAMS reveals an Altman Z-Score of 25.03 and a Piotroski F-Score of 1/9. These metrics, combined with its 5-year revenue trend ($0.02B most recent), help investors decide if NAMS fits their risk profile.

Question 3

What is the current P/E ratio for NAMS?

Accepted Answer

As of the latest trading session, NewAmsterdam Pharma Company N.V. (NAMS) has a trailing P/E ratio of -19.15.

Question 4

Who is the CEO of NewAmsterdam Pharma Company N.V.?

Accepted Answer

The current Chief Executive Officer of NewAmsterdam Pharma Company N.V. is Michael Harvey Davidson Facp..

Question 5

What was NAMS's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, NewAmsterdam Pharma Company N.V. reported annual revenues of $0.02B (2025), $0.05B (2024), $0.01B (2023), $0.10B (2022), $0.00B (2021) respectively.

Question 6

Does NAMS pay a dividend?

Accepted Answer

NewAmsterdam Pharma Company N.V. does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does NAMS have?

Accepted Answer

In its latest reporting period, NewAmsterdam Pharma Company N.V. generated $-0.15B in Free Cash Flow against a total debt load of $0.00B.

Question 8

What is the Price-to-Book (P/B) ratio of NewAmsterdam Pharma Company N.V.?

Accepted Answer

The Price-to-Book (P/B) ratio for NewAmsterdam Pharma Company N.V. (NAMS) is currently 5.71.

Question 9

What is the Price-to-Sales (P/S) ratio of NAMS?

Accepted Answer

Based on trailing twelve-month data, NewAmsterdam Pharma Company N.V. (NAMS) trades at a Price-to-Sales (P/S) ratio of 174.33.

Question 10

What is NewAmsterdam Pharma Company N.V.'s Return on Equity (ROE)?

Accepted Answer

NewAmsterdam Pharma Company N.V. (NAMS) has a Return on Equity (ROE) of -27.47%, representing its profitability relative to shareholder equity.

Period	Revenue	Gross Profit	Op. Income	Net Income	EPS
2025-12	22.5M	22.4M	-225.7M	-203.8M	-1.75
2024-12	45.6M	45.6M	-176.3M	-241.6M	-2.56
2023-12	14.1M	14.1M	-183M	-176.9M	-2.15
2022-12	102.7M	102.7M	-3.6M	-22.6M	-1.19
2021-12	0	0	-35M	-41.8M	-3.34

Period	Revenue	Gross Profit	Op. Income	Net Income	EPS
2025-12	22.5M	22.4M	-225.7M	-203.8M	-1.75
2024-12	45.6M	45.6M	-176.3M	-241.6M	-2.56
2023-12	14.1M	14.1M	-183M	-176.9M	-2.15
2022-12	102.7M	102.7M	-3.6M	-22.6M	-1.19
2021-12	0	0	-35M	-41.8M	-3.34